Criteria for Prior Authorization — Juvenile Idiopathic Arthritis (JIA) Agents
Customize your policy alerts
Sign up for all Kansas Department of Health and Environment policy alerts
Know when Kansas Department of Health and Environment releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization requirements, approved agents, dosing/age limits, initial and renewal criteria, and length of approval for biologic and JAK therapies used to treat juvenile idiopathic arthritis for members covered by the payer.
No material clinical or coverage changes in this revision.
Coverage Criteria for JIA Agents
Initial Therapy
Covered when ALL of the following are met
Initial approval length: 12 months
Continuation Therapy / Renewal
Covered when ALL of the following are met
Renewal approval length: 12 months
Concurrent use of more than one biologic or JAK inhibitor listed in this policy is not allowed. Requests for a biologic or JAK inhibitor will be denied if the patient is currently receiving another agent listed in Table 3 (initial requests) or Table 4 (renewals). After discontinuing the current biologic or JAK inhibitor, authorization for a new agent will not be issued until the next scheduled dose of the discontinued agent.
See Table 3 for agents that cannot be used concurrently with a requested initial biologic or JAK inhibitor and Table 4 for agents that cannot be used concurrently at renewal; concurrent use with any agent listed in these tables is prohibited.
Initial prior authorization requires documentation that the medication is FDA‑approved for the requested indication, age, and weight and that dosing does not exceed the limits in Table 1. The prescriber must document an adequate trial of methotrexate of at least 90 consecutive days, or a contraindication to methotrexate plus an adequate trial of at least one other conventional therapy (or contraindication to all conventional therapies in Table 2). For tofacitinib and upadacitinib, an adequate trial of at least one TNF blocker of at least 8 weeks or a contraindication to all TNF blockers is required. Prescriptions must be written by or in consultation with a rheumatologist, and baseline disease activity must be documented as cJADAS > 2.5 for initial approval.
Provider Actions, Authorization & Documentation
Prior authorization required for all listed JIA biologics and JAK inhibitors
Prior authorization is required for all current and future dose forms of the listed JIA biologics and JAK inhibitors. Approvals must meet FDA‑approved indication, age, weight (if applicable), and dosing limits listed in Table 1, and the medication must be prescribed by or in consultation with a rheumatologist. Preferred PDL drug is required when applicable unless the patient meets non-preferred PDL PA criteria.
- PA required for all listed JIA biologics and JAK inhibitors (all dose forms).
- Must meet FDA‑approved indication, age, weight, and Table 1 dosing limits.
- Prescribed by or in consultation with a rheumatologist.
- Preferred PDL drug required when applicable unless non-preferred PDL PA criteria met.
Required trials of methotrexate and TNF blocker(s) before initial authorization
Initial authorization requires documentation of an adequate trial of methotrexate (at least 90 consecutive days) or a contraindication to methotrexate plus an adequate trial of at least one other conventional therapy (or contraindication to all conventional therapies listed in Table 2). For tofacitinib and upadacitinib specifically, an adequate trial (at least 8 weeks) of at least one TNF blocker or contraindication to all TNF blockers is required.
- Methotrexate adequate trial: ≥ 90 consecutive days, or documented contraindication.
- If methotrexate contraindicated: adequate trial of ≥1 other conventional therapy from Table 2 or contraindication to all conventional therapies.
- Tofacitinib and upadacitinib: adequate trial ≥8 weeks of ≥1 TNF blocker or contraindication to all TNF blockers.
Clinical documentation the prescriber must submit
Prescriber must provide baseline and trial documentation with the initial request and response documentation for renewals: include the JIA indication, patient age and weight as applicable, documentation of prior trials or contraindications (methotrexate ≥90 days or other conventional therapy if applicable; TNF blocker trial ≥8 weeks when required), and baseline disease activity (cJADAS score > 2.5). For renewal, prescriber must document response defined as cJADAS‑10 ≤ 2.5 and that dosing remains within Table 1 limits.
- Initial requests: indication, age/weight (if applicable), prior trial of methotrexate (≥90 consecutive days) or documented contraindication, trial of other conventional therapy if methotrexate contraindicated, and baseline cJADAS > 2.5.
- Tofacitinib/upadacitinib initial requests: documentation of TNF blocker trial (≥8 weeks) or contraindication to all TNF blockers when required.
- Renewals: document response measure (cJADAS‑10 ≤ 2.5) and that dosing does not exceed Table 1 limits.
Denial risk for noncompliant dosing, age/weight limits, or duplicate biologic/JAK therapy
Requests are at risk of denial if the requested agent or dosing exceeds the FDA‑approved age, weight, or dosing limits in Table 1, or if the patient is currently receiving another biologic or JAK inhibitor listed in the policy (concurrent use not allowed).
- Dosing, age, weight must not exceed Table 1 limits — noncompliance may lead to denial.
- Concurrent use: patient must not be on another biologic or JAK inhibitor listed in Table 3/4; requests for concurrent therapy will be denied.
- After discontinuing a current biologic or JAK inhibitor, authorization for a new agent will not be granted until the next scheduled dose of the discontinued agent.
Included Agents, Age/Dosing Limits, and Codes
| Abatacept | Orencia® (listed agent) |
| Adalimumab | Humira®, Abrilada™, Amjevita™, Cyltezo®, Hadlima™, Hulio®, Hyrimoz®, Idacio®, Simlandi®, Yuflyma®, Yusimry™ |
| Canakinumab | Ilaris® |
| Certolizumab | Cimzia® |
| Etanercept | Enbrel®, Erelzi™, Eticovo® |
| Golimumab | Simponi Aria® |
| Sarilumab | Kevzara® |
| Tocilizumab | Actemra®, Tofidence™, Tyenne® |
| Tofacitinib | Xeljanz® tablets/oral solution |
| Upadacitinib | Rinvoq®, Rinvoq® LQ |
Definitions and Thresholds
Background
This policy applies to biologic disease‑modifying antirheumatic drugs (bDMARDs) and Janus kinase (JAK) inhibitors used to treat polyarticular juvenile idiopathic arthritis (PJIA) and systemic JIA (SJIA). It defines FDA‑approved age, weight, and dosing limits (see Table 1), required prior conventional therapy trials, prescriber specialty requirements, and disease activity thresholds for initial and renewal authorizations. Approvals are limited to the indications, ages, and dosing listed in the policy and follow the listed prior authorization and renewal criteria, including the prohibition on concurrent use of agents in Tables 3 and 4.
Revision History
Initial approval/effective date of the JIA prior authorization criteria.
Policy revised (entry listed among prior revision dates).
Policy revised (entry listed among prior revision dates).
Policy revised (entry listed among prior revision dates).
Policy revised (entry listed among prior revision dates).
Most recent comprehensive revision to the JIA prior authorization criteria (document shows 'Last revised 2024-10-16').
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.